ASND — Ascendis Pharma A/S Cashflow Statement
0.000.00%
Last trade - 00:00
- $13.88bn
- $14.34bn
- €266.72m
- 27
- 21
- 76
- 36
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -218 | -419 | -384 | -583 | -481 |
Depreciation | |||||
Amortisation | |||||
Non-Cash Items | 22.3 | 138 | -2.56 | 89.2 | 124 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 13.1 | -0.047 | -46.9 | -19.6 | -129 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -176 | -272 | -418 | -496 | -467 |
Capital Expenditures | -5.16 | -21.6 | -24.2 | -14.5 | -2.44 |
Purchase of Fixed Assets | |||||
Software Development Costs | |||||
Other Investing Cash Flow Items | — | -270 | -86.3 | 76.2 | 289 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -5.16 | -291 | -111 | 61.7 | 286 |
Financing Cash Flow Items | -31.7 | -31.4 | — | — | -1.81 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 494 | 603 | 351 | 397 | 134 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 320 | -13.6 | -138 | -1.5 | -52.6 |